References
- National Center for Health Statistics. Health, United States, 2005
- Grundy SM, Cleeman JI, Merz CN, . Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Arterioscler Thromb Vasc Biol, 2004; 24: 149–61
- Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials J Am Coll Cardiol, 2005; 45: 185–97
- McKenney J. New perspectives on the use of niacin in the treatment of lipid disorders Arch Intern Med, 2004; 164: 697–705
- Goldberg AC. A meta-analysis of randomized controlled studies on the effects of extended-release niacin in women Am J Cardiol, 2004; 94: 121–4
- Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES. Increasing HDL cholesterol with extended-release nicotinic acid: from promise to practice Neth J Med, 2004; 62: 229–34
- NIASPAN®: Niacin extended-release tablets. Cranbury, NJ: Kos Pharmaceuticals, Inc. 2005
- Goldberg AC. Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study Am J Cardiol, 1998; 82: 35–8Udiscussion 9–41U
- Goldberg A, Alagona P Jr, Capuzzi DM, . Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia Am J Cardiol, 2000; 85: 1100–5
- Hiatt JG, Shamsie SG, Schectman G. Discontinuation rates of cholesterol-lowering medications: implications for primary care Am J Manag Care, 1999; 5: 437–44
- Guyton JR, Goldberg AC, Kreisberg RA, . Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia Am J Cardiol, 1998; 82: 737–43
- Capuzzi DM, Guyton JR, Morgan JM, . Efficacy and safety of an extended-release niacin (Niaspan): a long-term study Am J Cardiol, 1998; 82: 74–81U; discussion 5–6U
- Marcelino JJ, Feingold KR. Inadequate treatment with HMG-CoA reductase inhibitors by health care providers Am J Med, 1996; 100: 605–10
- Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals Arch Intern Med, 2000; 160: 459–67
- Latts LM. Assessing the results: phase 1 hyperlipidemia outcomes in 27 health plans Am J Med, 2001; 110(Suppl 6A):17–23S
- Stone NJ, Bilek S, Rosenbaum S. Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options Am J Cardiol, 2005; 96: 53–9E